English  |  正體中文  |  简体中文  |  2809390  
???header.visitor??? :  27007657    ???header.onlineuser??? :  501
???header.sponsordeclaration???
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
???ui.leftmenu.abouttair???

???ui.leftmenu.bartitle???

???index.news???

???ui.leftmenu.copyrighttitle???

???ui.leftmenu.link???

"clancy j s"???jsp.browse.items-by-author.description???

???jsp.browse.items-by-author.back???
???jsp.browse.items-by-author.order1??? ???jsp.browse.items-by-author.order2???

Showing items 1-8 of 8  (1 Page(s) Totally)
1 
View [10|25|50] records per page

Institution Date Title Author
臺大學術典藏 2022-09-15T01:09:04Z Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial Shaw A.T.; Solomon B.J.; Chiari R.; Riely G.J.; Besse B.; Soo R.A.; Kao S.; Chia-Chi Lin; Bauer T.M.; Clancy J.S.; Thurm H.; Martini J.-F.; Peltz G.; Abbattista A.; Li S.; Ou S.-H.I.
臺大學術典藏 2022-09-15T01:08:57Z Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer Peters S.; Shaw A.T.; Besse B.; Felip E.; Solomon B.J.; Soo R.A.; Bearz A.; Gadgeel S.M.; Chia-Chi Lin; Kao S.; Seto T.; Masters E.T.; Abbattista A.; Clancy J.S.; Thurm H.; Reisman A.; Peltz G.; Ross Camidge D.
臺大學術典藏 2020-05-25T07:35:09Z Impact of lorlatinib on patient-reported outcomes (PROs) in patients (Pts) with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC) Peters S; Shaw A.T; Besse B; Felip E; Solomon B.J; Soo R.A; Bearz A; Gadgee S.M; Chia-Chi Lin; Kao S; Seto T; Masters E.T; Abbattista A; Clancy J.S; Thurm H; Reisman A; Camidge D.R.
臺大學術典藏 2020-05-25T07:35:07Z ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non�Vsmall-cell lung cancer Shaw A.T; Solomon B.J; Besse B; Bauer T.M; Chia-Chi Lin; Soo R.A; Riely G.J; Ignatius Ou S.-H; Clancy J.S; Li S; Abbattista A; Thurm H; Satouchi M; Camidge D.R; Kao S; Chiari R; Gadgeel S.M; Felip E; Martini J.-F.
臺大學術典藏 2020-05-25T07:35:07Z Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study Solomon B.J; Shaw A.T.; Ignatius Ou S.-H; Thurm H; Peltz G; Besse B; Bauer T.M; Felip E; Soo R.A; Camidge D.R; Chiari R; Bearz A; Chia-Chi Lin; Gadgeel S.M; Riely G.J; Tan E.H; Seto T; James L.P; Clancy J.S; Abbattista A; Martini J.-F; Chen J
臺大學術典藏 2020-05-25T07:34:59Z Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer Peters S; Shaw A.T; Besse B; Felip E; Solomon B.J; Soo R.A; Bearz A; Gadgeel S.M; Chia-Chi Lin; Kao S; Seto T; Masters E.T; Abbattista A; Clancy J.S; Thurm H; Reisman A; Peltz G; Ross Camidge D.
臺大學術典藏 2019 Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1�V2 trial Ou S.-H.I.;Li S;Abbattista A;Peltz G;Martini J.-F;Thurm H;Clancy J.S;Bauer T.M;Chia-Chi Lin;Kao S;Soo R.A;Besse B;Riely G.J;Chiari R;Solomon B.J;Shaw A.T; Shaw A.T; Solomon B.J; Chiari R; Riely G.J; Besse B; Soo R.A; Kao S; Chia-Chi Lin; Bauer T.M; Clancy J.S; Thurm H; Martini J.-F; Peltz G; Abbattista A; Li S; Ou S.-H.I.
臺大學術典藏 2019 Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1�V2 trial Ou S.-H.I.;Li S;Abbattista A;Peltz G;Martini J.-F;Thurm H;Clancy J.S;Bauer T.M;Chia-Chi Lin;Kao S;Soo R.A;Besse B;Riely G.J;Chiari R;Solomon B.J;Shaw A.T; Shaw A.T; Solomon B.J; Chiari R; Riely G.J; Besse B; Soo R.A; Kao S; Chia-Chi Lin; Bauer T.M; Clancy J.S; Thurm H; Martini J.-F; Peltz G; Abbattista A; Li S; Ou S.-H.I.

Showing items 1-8 of 8  (1 Page(s) Totally)
1 
View [10|25|50] records per page